Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs Tirzepatide in Type 2 Diabetes
NCT06534411Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised trial of cagrilintide and semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Change in Glycated Haemoglobin (HbA1c) at 60 weeks and Relative Change in Body Weight at 60 weeks. Started Nov 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06534411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534411.